Gregory George Acquires 2,324,072 Shares of Mesoblast (NASDAQ:MESO) Stock

April 11, 2026 by InsiderTrades.com

Key Points

Director Gregory George bought 1,981,890 shares on April 9 at $8.59 for $17,024,435.10 and also purchased 2,324,072 and 4,000,000 shares earlier in April, boosting his holdings to 13,586,890 shares (about a 17.08% increase).
Regulatory milestone: Mesoblast received FDA IND clearance to proceed directly to a registrational trial for Ryoncil in Duchenne muscular dystrophy, advancing a key program toward potential approval.
Market signals are mixed: an analyst cut the price target to $15.33 and ASX-listed MSB fell ~11% despite the IND clearance, while NASDAQ MESO opened near $15 with a market cap of roughly $1.94 billion.

Mesoblast Limited (NASDAQ:MESO - Get Free Report) Director Gregory George acquired 2,324,072 shares of the firm's stock in a transaction on Friday, April 10th. The stock was purchased at an average cost of $1.48 per share, with a total value of $3,439,626.56. Following the completion of the transaction, the director owned 8,324,072 shares in the company, valued at $12,319,626.56. The trade was a 38.73% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

Gregory George also recently made the following trade(s):

On Thursday, April 9th, Gregory George acquired 1,981,890 shares of Mesoblast stock. The stock was purchased at an average cost of $8.59 per share, with a total value of $17,024,435.10.
On Saturday, April 4th, Gregory George acquired 4,000,000 shares of Mesoblast stock. The stock was purchased at an average cost of $1.42 per share, with a total value of $5,680,000.00.

Mesoblast Stock Performance

NASDAQ:MESO opened at $15.00 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.58 and a quick ratio of 1.41. The firm has a 50-day moving average of $15.65 and a two-hundred day moving average of $16.81. The stock has a market cap of $1.94 billion, a P/E ratio of -27.78 and a beta of 2.19. Mesoblast Limited has a 1-year low of $9.75 and a 1-year high of $21.50.

Mesoblast (NASDAQ:MESO - Get Free Report) last posted its quarterly earnings data on Thursday, January 29th. The company reported ($0.16) earnings per share for the quarter. The business had revenue of $25.67 million for the quarter. On average, research analysts expect that Mesoblast Limited will post -0.7 earnings per share for the current fiscal year.

Key Headlines Impacting Mesoblast

Here are the key news stories impacting Mesoblast this week:

Positive Sentiment: Director Gregory George reported multiple large open-market purchases over April 4–10, including 4,000,000 shares at $1.42, 1,981,890 shares at $8.59, and 2,324,072 shares at $1.48 — filings show these trades increased his position materially (reported increases of ~17%–50%). Significant insider buying signals management confidence and can support the share price. SEC Form 4
Positive Sentiment: Mesoblast received IND clearance from the FDA to directly proceed to a registrational trial for Ryoncil® in Duchenne muscular dystrophy, and is partnering with patient groups (Parent Project Muscular Dystrophy, Duchenne Registry) for patient ID and trial awareness — this advances a key program toward potential approval, reducing regulatory uncertainty. FDA IND Clearance (Correction)
Neutral Sentiment: Management disclosed pipeline detail and platform updates at an R&D Day (transcript available) and held investor “show-and-tell” events — useful for long-term thesis but less likely to move price absent new data or milestones. R&D Day Transcript
Neutral Sentiment: Reported short interest shows 0 shares and 0.0 days-to-cover (likely a reporting/data anomaly). That reading should be treated cautiously; it provides no clear short-squeeze signal.
Negative Sentiment: An analyst price target cut (~-14.96% to $15.33) was published, which can pressure the stock by prompting repositioning by investors following coverage changes. Price Target Cut
Negative Sentiment: Australian market coverage showed MSB shares fell ~11% on the day despite the FDA clearance — suggesting region-specific selling, profit-taking, or concerns (e.g., dilution, timing, or commercialization path) are offsetting positive regulatory news. ASX Reaction

Hedge Funds Weigh In On Mesoblast

Several large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Mesoblast by 30.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,383 shares of the company's stock worth $43,000 after purchasing an additional 558 shares during the last quarter. Vanguard Personalized Indexing Management LLC lifted its holdings in Mesoblast by 5.4% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 14,047 shares of the company's stock worth $226,000 after acquiring an additional 716 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Mesoblast by 55.6% in the third quarter. JPMorgan Chase & Co. now owns 2,831 shares of the company's stock worth $46,000 after acquiring an additional 1,012 shares during the last quarter. Choreo LLC lifted its holdings in Mesoblast by 15.1% in the fourth quarter. Choreo LLC now owns 12,225 shares of the company's stock worth $227,000 after acquiring an additional 1,600 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new position in Mesoblast in the fourth quarter worth about $32,000. Institutional investors own 1.43% of the company's stock.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Mesoblast in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold".

Check Out Our Latest Analysis on MESO

Mesoblast Company Profile

(Get Free Report)

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company's most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn's disease.